View More
Short commentary from Dr. Martin Abrahamson on using SGLT2 inhibitors for cardiovascular and renal disease with type 2 diabetes, from CCO
Martin J. Abrahamson, MD, FACP
Physicians:
maximum of 0.25 AMA PRA Category 1 Credits™
Registered Nurses:
0.25 Nursing contact hours
Released: November 10, 2020
Expired:
November 9, 2021
CME commentary: GLP-1 receptor agonists and weight reduction in diabetes. Evidence for exenatide, dulaglutide, liraglutide, semaglutide in T2D and obesity.
Robert S. Zimmerman, MD
Physicians:
maximum of 0.25 AMA PRA Category 1 Credits™
Registered Nurses:
0.25 Nursing contact hours
Released: October 26, 2020
Expired:
October 25, 2021
Expert recommendations from Clinical Care Options on using oral semaglutide to treat type 2 diabetes
Richard E. Pratley, MD
Physicians:
maximum of 0.25 AMA PRA Category 1 Credits™
Registered Nurses:
0.25 Nursing contact hours
Released: October 22, 2020
Expired:
October 21, 2021
Concise CCO expert commentary on potential side effects with GLP-1 receptor agonists in patients with type 2 diabetes
Martin J. Abrahamson, MD, FACP
Physicians:
maximum of 0.25 AMA PRA Category 1 Credits™
Registered Nurses:
0.25 Nursing contact hours
Released: September 1, 2020
Expired:
August 31, 2021
Southern Medical Association, CME Division
3500 Blue Lake Drive, Suite 360
Birmingham, AL 35243
Tel: 800.423.4992, ext. 620
Email: Education@sma.org
Website: http://sma.org
You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.